Research Article

An ICT-Based Diabetes Management System Tested for Health Care Delivery in the African Context

Table 3

Evaluation of the impact of the use of Mobil Diab on the clinical results: intervention group versus control group.
(a) Intervention group: clinical results, changes in the quality of metabolic control after 60 days trial, and mean HbA1C for the intervention group before the beginning of the study which was 8.67%

Patients
(sex, age)
Mean BG (mg/dL)
day1–day60
Standard deviation (mg/dL) HbA1C (%)
day1–day60

P1 (M, 54)208.291.98.8
P2 (F, 38)
P3 (M, 52)95.31.55.4
P4 (M, 58)76.34.04.8
P5 (F, 60)108.832.65.8
P6 (M, 48)128.444.56.4
P7 (M, 55)303.784.411.7
P8 (F, 49)
P9 (M, 48)130.038.46.4
P10 (M, 62)141.448.06.8
P11 (M, 51)180.115.87.9
P12 (M, 56)134.238.06.6
P13 (M, 57)
P14 (M, 43)111.511.15.9
P15 (M, 60)132.732.66.5
P16 (M, 58)128.830.36.4
P17 (M, 50)157.430.07.3
P18 (F, 35)11110.95.9
P19 (M, 70)10814.55.8
P20 (M, 62)116.331.86.0

53.3
Mean age,
St. deviation
10.7
143.5

Mean blood
glucose
33.0

Mean BG
St. deviation
6.89

Mean HbA1C
at the end

(b) Control group: clinical results, changes in the quality of metabolic control after 60 days trial, and mean HbA1C for the control group before the beginning of the study which was 8.59%

Patients
(sex and age)
Mean BG (mg/dL)
day1–day60
Standard deviation (mg/dL) HbA1C (%)
day1–day60

Pc1 (M, 43)261.844.210.4
Pc2 (M, 55)187.28.2
Pc3 (M, 60)17448.27.8
Pc4 (F, 37)227.833.29.4
Pc5 (M, 48)
Pc6 (M, 67)175.717.77.8
Pc7 (F, 40)15929.57.3
Pc8 (M, 42)202.98.6
Pc9 (M, 57)299.5101.411.5
Pc10 (F, 53)
Pc11 (M, 59)
Pc12 (M, 66)
Pc13 (M, 54)163.235.17.4
Pc14 (M, 45)
Pc15 (F, 58)269.480.610.6
Pc16 (M, 61)184.268.48.1
Pc17 (M, 75)181.371.88.0
Pc18 (F, 49)
Pc19 (F, 52)180.412.68
Pc20 (F, 46)160407.3

53.35
Mean age,
St. deviation
9.59
201.9

Mean blood
glucose
48.6

Mean BG
St. deviation
8.6

Mean HbA1C
at the end

(St. deviation: standard deviation, mean BG: mean blood glucose values).